Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily: Axinn Veltrop & Harkrider LLP

News

Email Page

Chad Landmon Discusses At-Risk Launches with The Pink Sheet Daily

Teva recently agreed to settle its long-running patent litigation with Novartis over the herpes drug Famvir (famciclovir) by making a one-time payment to Novartis. Teva will also continue to pay royalties on U.S. sales of the generic version of Famvir. This payment covers damages from Teva’s at-risk launch of Famvir in September of 2007.

Because Teva's launch was at-risk, and because Teva has now been forced to settle with Novartis by paying royalties on is past and future sales, Chad Landmon, Partner at Axinn Veltrop & Harkrider, tells The Pink Sheet that this settlement may very well curtail some at-risk launches . Specifically, Landmon said that the Famvir settlement "may lead generic companies to question more thoroughly the decision to launch at risk.”

The article, entitled “Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis,” was published by The Pink Sheet on February 16, 2010.

AVH: One of only a handful of firms named to the National Law Journal's "Mid-size Hot List"

World Class: Founded by three lawyers from Skadden, Arps who were quickly joined by other lawyers who shared a common vision, both from government and from other firms such as Dewey & LeBoeuf, Sullivan & Cromwell and Simpson Thacher.

Unsurpassed Reputation: Our attorneys have handled some of the largest and most challenging antitrust matters in recent years, including the largest cash merger in U.S. history and a wide array of cutting-edge litigation and counseling matters.

Our industry focus includes:

Biomedical Biotechnology Medical Devices Pharmaceuticals Chemistry/Chemical Engineering Computer Software and Systems Mechanical

Unique Value: We understand the particular business goals of our clients, the nuances of the law and the strategies needed to exploit the technical subject matter at issue.

Track Record: All of the firm's lawyers are accomplished litigators who bring to every case an effective combination of general litigation skills, such as persuasive advocacy and procedural tactics, and experience in particular areas of the law.

AVH attorneys are thought leaders in their areas of concentration. We are often quoted in trade journals, national media, and speak frequently at industry events.

Join Us: AVH has among its ranks some of the most talented antitrust, IP, and litigation and regulatory attorneys in the country.